These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22075663)

  • 1. Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case.
    Itatani Y; Akiyoshi T; Kuroyanagi H; Yamakawa K; Noaki R; Konishi T; Fujimoto Y; Ueno M; Oya M; Suenaga M; Yamaguchi T
    Surg Today; 2012 Jan; 42(1):75-9. PubMed ID: 22075663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of unresectable rectal cancer with severe pelvic infiltration responding to FOLFOX].
    Yamazoe S; Yamaguchi K; Terasawa H; Ojima T; Tsujimura H; Shimomura T
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):125-8. PubMed ID: 21368473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab].
    Kuwabara H; Watanabe S; Liu B; Mitsuoka A; Sanada T; Nakajima K; Goseki N
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2032-4. PubMed ID: 24394003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laparoscopic abdominosacral resection for locally advanced primary rectal cancer after treatment with mFOLFOX6 plus bevacizumab, followed by preoperative chemoradiotherapy.
    Nagasaki T; Akiyoshi T; Ueno M; Fukunaga Y; Nagayama S; Fujimoto Y; Konishi T; Yamaguchi T
    Asian J Endosc Surg; 2014 Jan; 7(1):52-5. PubMed ID: 24450344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of locally advanced rectal cancer responding to FOLFOX].
    Kume S; Kubota T; Takahashi M; Hashimoto D; Hirata T; Torigoe Y; Ikeda O
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):659-61. PubMed ID: 19381043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case with liver resection of metastasis from rectal cancer after FOLFOX4+bevacizumab treatment].
    Kojima T; Matsui T; Uemura T; Fujimitsu Y; Kure N; Kojima H
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1761-3. PubMed ID: 18931584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
    Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
    Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case successfully treated with total pelvic exenteration after preoperative chemotherapy FOLFOX4 plus bevacizumab for unresectable sigmoid colon cancer with extramural progression].
    Yasue H; Hanyu N; Usuba T; Abe M
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):327-9. PubMed ID: 20154496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11].
    Takahashi T; Namiki K; Matsumoto H; Konno F; Mitsui K; Yoshida R
    Gan To Kagaku Ryoho; 2014 May; 41(5):653-5. PubMed ID: 24917016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
    Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of pathologically complete response in a patient with locally advanced sigmoid colon cancer after chemotherapy including bevacizumab/FOLFOX4].
    Mikami Y; Tamura N; Akiyama M; Muraoka T; Sakurai U; Sawabe M
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):777-9. PubMed ID: 25129094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].
    Suzuki S; Shigaki N; Yokoyama S; Yamashita H; Sugita H; Arima N
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1545-7. PubMed ID: 21918360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX.
    Liang JT; Lai HS; Cheng KW
    Surg Endosc; 2011 Jan; 25(1):305-8. PubMed ID: 20526625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.
    Spigel DR; Bendell JC; McCleod M; Shipley DL; Arrowsmith E; Barnes EK; Infante JR; Burris HA; Greco FA; Hainsworth JD
    Clin Colorectal Cancer; 2012 Mar; 11(1):45-52. PubMed ID: 21840771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
    Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case report of pathologically complete response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
    Miyazawa T; Ebe K; Fujita N; Koide N; Honma K; Ikarashi T
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):1001-3. PubMed ID: 22705702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.